Evidence map›Paper›PMID 34982784›Full record

ArticlePloS one2022

(More than) doubling down: Effective fibrinolysis at a reduced rt-PA dose for catheter-directed thrombolysis combined with histotripsy.

Samuel A Hendley, Aarushi Bhargava, Christy K Holland, Geoffrey D Wool, Osman Ahmed, Jonathan D Paul, Kenneth B Bader

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Frontiers in physiology · 2023
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samuel A HendleyCommittee on Medical Physics, University of Chicago, Chicago, Illinois, United States of America.
Aarushi BhargavaDepartment of Radiology, University of Chicago, Chicago, Illinois, United States of America.
Christy K HollandDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, United States of America.
Geoffrey D WoolDepartment of Pathology, University of Chicago, Chicago, Illinois, United States of America.
Osman AhmedDepartment of Radiology, University of Chicago, Chicago, Illinois, United States of America.
Jonathan D PaulDepartment of Medicine, University of Chicago, Chicago, Illinois, United States of America.
Kenneth B BaderCommittee on Medical Physics, University of Chicago, Chicago, Illinois, United States of America.ORCID 0000-0003-2384-3150

Funding

Treatment of chronic venous thrombosis with histotripsy and thrombolyticsR01HL133334 · NHLBI · UNIVERSITY OF CHICAGO · PI Kenneth B. Bader · 2018 to 2026
$5.7M
NHLBI NIH HHS R01 HL133334
6 · The paper itself

Abstract

Deep vein thrombosis is a major source of morbidity and mortality worldwide. For acute proximal deep vein thrombosis, catheter-directed thrombolytic therapy is an accepted method for vessel recanalization. Thrombolytic therapy is not without risk, including the potential for hemorrhagic bleeding that increases with lytic dose. Histotripsy is a focused ultrasound therapy that generates bubble clouds spontaneously in tissue at depth. The mechanical activity of histotripsy increases the efficacy of thrombolytic therapy at doses consistent with current pharmacomechanical treatments for venous thrombosis. The objective of this study was to determine the influence of lytic dose on histotripsy-enhanced fibrinolysis. Human whole blood clots formed in vitro were exposed to histotripsy and a thrombolytic agent (recombinant tissue plasminogen activator, rt-PA) in a venous flow model perfused with plasma. Lytic was administered into the clot via an infusion catheter at concentrations ranging from 0 (control) to 4.54 μg/mL (a common clinical dose for catheter-directed thrombolysis). Following treatment, perfusate samples were assayed for markers of fibrinolysis, hemolysis, and intact red blood cells and platelets. Fibrinolysis was equivalent between the common clinical dose of rt-PA (4.54 μg/mL) and rt-PA at a reduction to one-twentieth of the common clinical dose (0.23 μg/mL) when combined with histotripsy. Minimal changes were observed in hemolysis for treatment arms with or without histotripsy, potentially due to clot damage from insertion of the infusion catheter. Likewise, histotripsy did not increase the concentration of red blood cells or platelets in the perfusate following treatment compared to rt-PA alone. At the highest lytic dose, a refined histotripsy exposure scheme was implemented to cover larger areas of the clot. The updated exposure scheme improved clot mass loss and fibrinolysis relative to administration of lytic alone. Overall, the data collected in this study indicate the rt-PA dose can be reduced by more than a factor of ten and still promote fibrinolysis when combined with histotripsy.

Indexed as

Blood PlateletsCathetersErythrocytesFibrinolysisFibrinolytic AgentsHemoglobinsHumansIn Vitro TechniquesRecombinant ProteinsThrombolytic TherapyTissue Plasminogen ActivatorVenous ThrombosisFibrinolytic AgentsHemoglobinsRecombinant ProteinsTissue Plasminogen Activator

Identifiers

PMID34982784
PMCPMC8726487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.